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Background: There is revived interest in home hemodialysis (HD), which is spurred by cost containment
and experience indicating lower mortality risk compared with facility HD and peritoneal dialysis (PD). Social
barriers to home HD include disruptions to the home environment, interference with family life, overburdening
of support networks, and fear of social isolation. A submodality of home HD, in which patients from urban
settings undertake independent HD in unstaffed nonmedical community-based home-like settings, is de-
scribed in this study. The survival of patients treated in this manner is compared with that of those using
conventional home HD.
Study Design: An observational cohort study using the Australia and New Zealand Dialysis and Transplant
Registry.
Setting & Participants: All adult patients starting renal replacement therapy in New Zealand since March
31, 2000, followed up through December 31, 2010.
Predictor: The main predictor was time-varying dialysis modality (home HD, facility HD, PD, and community
house HD), adjusting for the confounding effects of patient demographics and time-varying comorbid
conditions.
Outcome: Patient mortality.
Results: 4,709 patients with 12,883 patient-years of follow-up (5,591, PD; 1,532, home HD; 5,647, facility
HD; and 113, community house HD) were analyzed. Community house HD patients were younger, healthier,
and more likely to be Pacific people than those using other modalities, including home HD. Relative to home
HD, adjusted mortality HRs were 2.18 (95% CI, 1.78-2.67) for facility HD, 2.17 (95% CI, 1.77-2.66) for PD, and
1.48 (95% CI, 0.64-3.40) for community house HD.
Limitations: Small number of patients receiving community house HD, possible residual confounding from
the limited collection of comorbid conditions (eg, no collection of cognitive or motor impairment), and absence
of socioeconomic, medication, and biochemical data in analyses.
Conclusions: Within limits, this study shows community house HD to be both safe and effective. Community
house HD provides an option to improve the uptake of home HD.
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Dialysis and Transplant Registry (ANZDATA).The most common dialysis modality globally isfacility hemodialysis (HD), followed by perito-
neal dialysis (PD).1,2 The least common is home HD,
which has become less used over time because of
unfavorable reimbursement and regulatory environ-
ments and an increasingly dependent end-stage kid-
ney disease population.3,4 However, home HD has
remained common in New Zealand, where 18% of
patients undertake their dialysis in this manner. In
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598New Zealand, it generally is held that patients on
home HD therapy achieve better metabolic and fluid
control, and probably fewer comorbid conditions and
lower mortality.5-7
Recently, there has been a global resurgence of
interest in home HD driven by the need for cost
containment and cumulative clinical experience of
better patient experience and outcomes.8,9 This is
particularly so for frequent/extended home HD, which
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Community House HDis the most physiologically restorative dialysis modal-
ity.10-12 However, barriers to the uptake of home HD
are considerable. Even in New Zealand, there is a
stable prevalence of this modality despite resolute
advocacy by both dialysis clinicians and patient groups.
Important patient-level barriers include the potential
for disruption to the physical home environment,
interference with family life, overburdening of care-
giver/helper support, financial disadvantage from out-
of-pocket expenses, and fear of social isolation.13-15
Since 2004, an initiative has been ongoing in parts
of New Zealand to provide home HD to patients who
are capable, but unable or unwilling to do HD in their
own home. This submodality of home HD has been
described previously for the treatment of very isolated
patients in Western Australia and involves patients
performing independent HD without direct nursing or
medical supervision in unstaffed nonmedical commu-
nity-based home-like settings.16-18 The terms used
previously include “community home HD” or “com-
munity house HD.” In the New Zealand initiative,
community house HD allows patients from urban
centers to perform their HD in shared suburban loca-
tions either by themselves or with another patient for
support and company. Our community house HD
initiative originated as collaboration between provid-
ers and patient support groups and remains an effec-
tive and durable submodality with ongoing active
input from both groups.
In this article, we describe the outcome of commu-
nity house HD patients in New Zealand and review
the origins and development of the community house
HD initiative to date. We compare mortality risk in
patients treated with community house HD with that
of patients treated with other dialysis modalities,
using the Australia and New Zealand Dialysis and
Transplant Registry (ANZDATA; www.anzdata.org.
au), which has prospectively collected data for pa-
tients with end-stage kidney disease in these countries
since 1963.19
METHODS
StudyDesign
We performed a cohort study using an as-treated framework
(“did the exposure that the patient actually receive affect mortal-
ity?”), as opposed to an intention-to-treat framework (“did expo-
sure that the patient initially receive affect mortality, irrespective
of subsequent changes that occurred along the way?”). We per-
formed analyses of patients until death or censoring using time-to-
event statistical models.
Participants
We created an inception cohort of incident adult patients with
end-stage kidney disease (aged 18 years at dialysis inception)
whose first treatment occurred on or after April 1, 2000, in New
Zealand. Patients were followed up until death or December 31,
Am J Kidney Dis. 2013;61(4):598-6072010, whichever occurred first. Censoring was at the time of
kidney transplantation, return of kidney function, or loss to
follow-up.
CommunityHDHouse Setting
The settings of interest in our study are the community HD
houses (photographs available in Fig S1, provided as online
supplementary material). These are located in 2 of the 12 District
Health Boards in New Zealand: Counties Manukau and Hawke’s
Bay District Health Boards. Populations of both District Health
Boards can be summarily described as being young, multiethnic,
and socioeconomically disadvantaged. Counties Manukau is a
large urban District Health Board serving 491,270 at the end of the
study period, and Hawke’s Bay is a smaller mixed urban and rural
District Health Board serving 154,770.
The first community house HD treatments began in early 2001,
when a home HD patient could not dialyze at home for social
reasons. He or she was set up to dialyze independently on the
suburban premises of a nephrology-orientated charitable society,
the Kidney Society Auckland (www.kidneysociety.co.nz). After
this particular home HD patient underwent kidney transplantation,
2 others dialyzing in a facility expressed an interest to also dialyze
in this manner and were trained and transitioned to undertake their
own treatments in the same setting. In response to increased
demand, the Kidney Society Auckland purchased a residential
property in 2004 within 1 km of the main tertiary referral hospital
in the region. The house subsequently was equipped for HD and
fitted out with donated secondhand furniture to create a “homey”
environment. A partnership was entered into between Counties
Manukau District Health Board and the Kidney Society Auckland
to formalize the initiative, and the first dedicated community HD
house in New Zealand opened in May 2004. The house has room
for up to 7 HD machines, allowing a maximum of 14 patients (that
is, 7 pairs) to dialyze at the house. Each pair of patients shares a
machine, organizing their rosters between themselves. A total of 48
patients have used the house to date, including a single nocturnal
dialysis patient.
A second partnership was entered into between Counties Manu-
kau District Health Board and a primary health care trust in 2005,
and a second community HD house was opened in May of that
year in an annex to a local family practice center. This could
accommodate up to 10 patients, although it was hampered by
mainly having single rooms and a clinical rather than homey
ambience. Probably as a result of this, only 14 patients ever used
the house, with average occupancy of 50%-60%. The house was
closed in December 2008. A third community HD house was
opened by Counties Manukau District Health Board in a small
rural aged-care and home health facility in October 2005 without
partnering with a charitable society. This could accommodate up to
4 patients, and 7 patients used the house until its closure in July
2007 due to lack of demand.
Hawke’s Bay District Health Board and the Wairoa Dialysis
Society opened the Wairoa Community HD House in September
2010. This can accommodate up to 12 patients, and a total of 2
patients have used the house to date, including a single patient on
daily dialysis. The Wairoa Community HD House is located in a
suburban setting, albeit in a relatively isolated town in New
Zealand, some 1.5 hours from the nearest staffed HD facility.
As per the philosophy of community house HD, the modality is
offered to those deemed to be capable, but unable or unwilling to
do HD in their own home. It is available as a modality choice in
incident patients with end-stage kidney disease, but also to appro-
priate patients already receiving dialysis therapy in facilities. This
approach generally has amounted to recruitment of a certain local
demographic that otherwise remain ensconced on in-center dialy-
sis therapy: younger patients from socioeconomically disadvan-
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New Zealand Maori ethnicity and have been on dialysis therapy
for some time. To improve uptake and engagement by existing
dialysis patients, community house HD often is offered to pairs of
patients who are either friends or family members to both improve
the training and dialysis experience and mitigate any social isola-
tion that might otherwise be experienced by patients in the transi-
tion from facility to community house HD. The Counties Manukau
District Health Board houses have been sited in areas with an
average population density of 2,900/km2, and the corresponding
density is 11/km2 in the area of the Hawke’s Bay District Health
Board house.20 The precise locations are chosen to optimize
convenience for prospective patients and according to demand.
The following summarizes key elements of the organizational/
operational frameworks for community house HD. Patients are
trained and signed off for home HD by the District Health Board
and medically supported by the District Health Boards, as would
be the case if they were on home HD. The roles and responsibilities
of stakeholders in the program are as follows: the patients are
responsible for their dialysis, the charitable societies are respon-
sible for the community HD house premises, and the District
Health Boards are responsible for the supply of dialysis machines/
consumables. The District Health Boards and the charitable societ-
ies sign a legal agreement to cover an agreed proportion of
housekeeping and maintenance, running expenses, and nondialysis
supplies. At Counties Manukau District Health Board, patients
must be accepted by the charitable society as short- or long-term
guests and sign a detailed contract with the charitable society that
they understand and accept the rules of the program/house and
their responsibilities. From a provider (District Health Board)
perspective, the costs of the programs are met within business as
usual budgets. At Counties Manukau District Health Board, com-
munity house HD is more expensive than home HD by $NZ1,000-
$NZ2,000 per patient per annum.
The machines used for community house HD are the same as
those used for home HD in New Zealand and include the Fresenius
4008B machine (Fresenius Medical Care), but more commonly the
Gambro AK 200S and AK 96 machines (Gambro AB). Water is
treated through portable reverse-osmosis machinery with carbon
and sedimentation filters, most commonly with in-line dialysate
ultrafilters. A mixture of high- and low-flux dialyzers are used for
patients in the community house HD programs, as is the case for
most nonfacility HD across New Zealand.7 This is because of the
generally poor evidence for added clinical benefit from convective
clearance,21-23 which in home and community house HD settings
must be weighed on a case-by-case basis against the possibility of
microbiological or endotoxin contamination of home water sup-
plies and the increased risk of back-transfer through leakier dialyz-
ers.
There are several approaches to maximize safety during commu-
nity house HD. As stated, patients often are trained and scheduled
for dialysis in pairs, arrangements that usually are sustained in the
long term. In most houses, there are telephones with separate lines
in every room, and “panic alarms,” which are directly linked to
local paramedic services with their own access into the houses. In
the event of a triggered alarm, paramedics may call the room of the
house in question, but otherwise attend as a priority callout,
especially if there is no response.
Primary Exposure andOutcomeVariables
The primary exposure in this study was time-varying dialysis
modality: home HD, PD, facility HD, and community house HD.
We did not categorize HD modalities further as being frequent or
extended hours; a previous study in Australia and New Zealand has
shown mortality benefit with home HD and its related characteris-
tics, but not with frequent/extended operating characteristics per
600se.7 A lag of 90 days was allowed after a change of dialysis
modality so that deaths occurring within 90 days of a change were
attributed to the previous modality.
The primary outcome was patient mortality. Patient mortality
was based on details provided by the treating nephrologist.
DataMeasurement andQuantitativeVariables
We adjusted for known patient-related risk factors collected in
ANZDATA: age, sex, ethnicity, primary kidney disease, estimated
glomerular filtration rate (using the isotope-dilution mass spectrom-
etry–traceable 4-variable Modification of Diet in Renal Disease
[MDRD] Study equation24), late referral for nephrology predialy-
sis care (3 months before dialysis inception), diabetes mellitus
(none, type 1, and type 1), body mass index, comorbid conditions
(coronary artery disease, peripheral vascular disease, cerebrovascu-
lar disease, and chronic lung disease), smoking, serum hemoglobin
level, and year of treatment to account for any secular variation.
We did not include serum calcium/phosphate levels because these
data have been collected since only October 1, 2003. Comorbid
conditions are updated at each ANZDATA survey and are modeled
as time-varying carrying-forward observations from the last sur-
vey.
StatisticalMethods
We constructed models for survival using Cox proportional
hazards regression. Continuous covariates such as age and body
mass index were modeled as quantiles in order to avoid the
assumption of linear relationships with outcome. We removed
covariates from the multivariate model in a backward stepwise
fashion beginning with the covariate with the highest P value from
2-tailed Wald tests of the individual coefficients, using the partial
likelihood ratio test to compare the new reduced model with the
older larger model to confirm that the deleted covariate was not
significant. We based final confounder selection on both biological
plausibility and contribution to the comprehensibility of the model,
and also the significance of the covariate within the model as
assessed by the 2-tailed partial likelihood ratio test at P  0.2.
When we determined the final model, we reintroduced all covari-
ates that initially were considered but later removed, to confirm
that they were not statistically significant as an important con-
founder.
In the main exposure-outcome models, we included a -distrib-
uted shared frailty based on significance at a level 0.05 (as
assessed by the 2-tailed partial likelihood ratio test) using the
center of initial dialysis treatment as the grouping variable. This
procedure adds a random effect to model heterogeneity of effect
across defined groups and accounts in this case for the correlation
between patients within centers. Hazard ratios therefore estimate
the effect of the covariate of interest for any given level of frailty.
The assumption for proportional hazards for the final models
was assessed formally by the use of scaled Schoenfeld residuals
and visually by –ln(ln[survival]) versus ln(analysis time) plots
for modality, adjusted for confounders. We assessed overall good-
ness of fit visually by comparing plots of Kaplan-Meier observed
survival curves with the Cox predicted curves for modality.
We used interaction terms for the preliminary main-effects
model to test whether there was effect modification by sex, age,
and race. We chose these interactions as being clinically plausible
on the basis of both published literature and cumulative clinical
experience. Two- and 3-way interactions between HD dose and
these subgroups were assessed using 2-tailed Wald test P values as
a guide to selecting interaction terms for testing, with significance
within the model determined by a 2-tailed partial likelihood ratio
test P 0.05.
When necessary, comparisons between groups were made using
t test, Mann-Whitney U or Kruskal-Wallis test, or 2 test, as
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Community House HDappropriate. Statistical significance to associations was attributed
to findings for 2-tailed P  0.05. We used Stata Intercooled
MP/11.2 for analyses (StataCorp).
RESULTS
Participant andOutcomeData
We identified an inception cohort of 4,730 adult
patients with 12,994 patient-years of follow-up. There
were 4,709 patients with 12,883 patient-years of fol-
low-up with sufficient data for study: Table S1 summa-
Table 1. Clinical Characteristics o
Variable PD (n 2,649
Follow-up (patient-y) 5,591
Vintage at modality inception (d) 0 (0-45)
Age at modality inception (y) 60.4 (50.7-69.
Sex
Female 1,186 (45)
Male 1,463 (55)
Ethnicity
NZ European/other 1,280 (48)
NZ Maori 871 (33)
Asian 172 (6)
Pacific people 326 (12)
Late referral 582 (22)
eGFR at dialysis inception (mL/min/1.73 m2) 6.9 (4.9-9.6)
Smoking at dialysis inception 463 (17)
Diabetes mellitus
Type 1 94 (4)
Type 2 1,202 (45)
Primary kidney disease
Glomerulonephritis/other 1,136 (43)
Hypertension/Ischemic 347 (13)
Diabetic nephropathy 1,166 (44)
Comorbid disease at modality inception
Coronary artery 1,041 (39)
Peripheral vascular 662 (25)
Cerebrovascular 416 (16)
Lung 456 (17)
BMI at modality inception (kg/m2) 27.3 (23.9-31.
No. of patients with another modalitya
PD —
Home HD 124
Facility HD 1,554
Community house HD 18
Note: Unless otherwise indicated, categorical variables are s
median (interquartile range). Of note, clinical characteristics ar
multiple modality categories due to multiple exposures over the d
Abbreviations: BMI, body mass index; eGFR, estimated glome
Zealand.
aNumber of patients exposed to another modality during entirerizes differences between the inception and study
Am J Kidney Dis. 2013;61(4):598-607cohorts and describes the excluded cohort with miss-
ing data. We modeled 2,146 deaths, with 53% due to
cardiovascular causes, 14% due to infectious causes,
and the remainder due to treatment withdrawal, can-
cer, and other causes.
DescriptiveData
Table S1 summarizes patient characteristics at the
start of dialysis therapy in the study cohort, and Table
1 lists corresponding characteristics at modality incep-
Study Cohort at Modality Inception
HD
Home (n 714) Facility (n 3,608)
Community
House (n 59)
1,532 5,647 113
213 (124-445) 0 (0-0) 783 (238-1,942)
51.1 (41.3-59.1) 58.2 (48.4-66.9) 46.1 (28.0-52.7)
209 (29) 1,383 (38) 20 (34)
505 (71) 2,225 (62) 39 (66)
352 (49) 1,501 (42) 6 (10)
248 (35) 1,226 (34) 21 (36)
25 (4) 194 (5) 3 (5)
89 (12) 687 (19) 29 (49)
128 (18) 965 (27) 11 (19)
5.7 (3.9-7.6) 6.0 (4.3-8.5) 4.7 (3.0-6.7)
123 (17) 610 (17) 14 (24)
17 (2) 96 (3) 1 (2)
251 (35) 1754 (49) 22 (37)
425 (60) 1,574 (44) 35 (59)
54 (8) 378 (10) 4 (7)
235 (32) 1,656 (46) 20 (34)
163 (23) 1,318 (37) 7 (12)
65 (9) 791 (22) 5 (8)
34 (5) 468 (13) 2 (3)
89 (12) 625 (17) 9 (15)
29.6 (25.1-36.3) 28.7 (24.6-33.9) 31.6 (25.8-36.5)
124 1,554 18
— 708 39
708 — 56
39 56 —
are number (percentage); continuous variables are shown as
modality (not dialysis) inception. Patients may be classified in
n of the study.
filtration rate; HD, hemodialysis; PD, peritoneal dialysis; NZ, New
d of their follow-up.f the
)
3)
2)
hown
e at
uratio
rulartion (the point of the start of the respective dialysis
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Marshall et almodality). Some patients are classified in multiple
modality categories according to their exposure over
the duration of follow-up. Compared with patients
treated with facility HD or PD, those using home HD
were younger, mostly male, more likely to have end-
stage kidney disease secondary to single-organ (eg,
glomerulonephritis) rather than systemic disease, and
less likely to have diabetes mellitus or medical comor-
bid conditions. Those treated with community house
HD were similar, although they tended to be even
younger and even less likely to have medical comor-
bid conditions despite a higher tendency to smoke.
Patients treated with community house HD also tended
to be Pacific people or New Zealand Maori and often
were on dialysis therapy for some years before mak-
ing the transition to community house HD. Modality
transfers at the discontinuation of community house
HD was as follows: 12 were transferred to facility
HD, 19 were transferred to home HD, 2 underwent
kidney transplantation, and 4 died.
MainResults
Kaplan-Meier estimates of survival are shown in
Fig 1. The main-effects model (fully adjusted for all
main-effects confounders in Table 1) is presented in
Fig 2. Table 2 lists crude and multivariate effects of
modality as hazard ratios and 95% confidence inter-
vals for mortality. As expected, home HD was associ-
ated with significantly lower mortality risks relative to
facility HD and PD. Community house HD was
associated with a point estimate for adjusted mortality
risk that was similar to that of home HD, although
confidence intervals were wide, resulting in no signifi-
cant differences between community house HD and
0.00
0.25
0.50
0.75
1.00
P
ro
po
rti
on
 R
em
ai
ni
ng
 A
liv
e
0 2 4 6
Years
PD Facility HD
Home HD Communitythe other modalities for this parameter.
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There was no effect modification by sex, age, and
race. However, consistent with previous reports by
this group, the mortality risk associated with PD was
lower compared to other modalities in the initial
period post–dialysis inception and higher thereaf-
ter.7,25 Interactions with duration of follow-up are
listed in Table 2, with estimates of mortality risk
provided separately according to restricted follow-up
intervals. The interactions described are similar to
those reported elsewhere in the literature7,25 and likely
reflect a transplantation effect (healthier patients re-
ceive transplants and leave the home or community
house HD environment) and a comorbid condition
effect (sicker patients in facilities tend to die in the
first year or 2), with lessening of the relative differ-
ences in outcomes between the modalities over time.
Table 3 lists characteristics of the restricted cohort
of HD patients. Treatment characteristics of patients
at community house HD inception were intermediate
to those of patients treated with home HD and facility
HD. In particular, they had a distribution of HD
session length and frequency similar to patients receiv-
ing facility HD, with the most common regimen being
HD for 4-5 hours 3 times a week. The prevalence of
fistulas for angioaccess in those on community house
HD was similar to those undertaking home HD.
DISCUSSION
In this study, we have shown community house HD
to be a useful and sustainable submodality of home
HD. Community house HD seems to be safe and
effective, notwithstanding the limited sample size in
our study. In our experience, the effect of community
house HD on health-related quality of life also seems
10
e HD
Figure 1. Kaplan-Meier survival esti-
mates by modality, censored for transplanta-
tion, return of kidney function, and loss to
follow-up. Abbreviations: HD, hemodialysis;
PD, peritoneal dialysis.8to be positive and is one of our priority areas for
Am J Kidney Dis. 2013;61(4):598-607
Community House HDfurther formal study. Patient modality choices after
community house HD indicate that it is a final and
definitive option for some of them, but also a potential
“stepping stone” to home HD for others. The patients
in our study mostly came to community house HD
after having been in facilities for some years. Taken
together, these factors suggest a role for community
house HD to increase the uptake of home HD by
patients who would otherwise remain facility depen-
C
Perip
C
T
 T
Ischaemic Nephropathy
Other
Figure 2. Hazard ratios (log scale)
for mortality from the main-effects
model, fully adjusted for the confound-
ers in Table 1 (the marker represents
point estimates; the whiskers, 95%
confidence intervals). Abbreviations:
BMI, body mass index; HD, hemodi-
alysis; NZ, New Zealand; PD, perito-
neal dialysis.dent and is concordant with results of a recent survey
Am J Kidney Dis. 2013;61(4):598-607of 2,190 facility dialysis patients in Australia. In that
survey, willingness to undertake home dialysis was
greater when paid carers or nursing support was
offered and if expenses were reimbursed, but greatest
if the option of a community HD house was pro-
vided.26
Home HD is associated with lower cost and lower
mortality risk, as well as the best quality of life of all
dialysis modalities.7-9,27-34 It also is the easiest and
2008-2010
2004-2007
2000-2003
Late Referral
Vintage Tertile 3
Vintage Tertile 2
Vintage Tertile 1
Lung Disease
ovascular Disease
l Vascular Disease
ary Artery Disease
BMI >=30
BMI 25-29
BMI 20-24
BMI <20
2 Diabetes Mellitus
1 Diabetes Mellitus
 Diabetes Mellitus
betic Nephropathy
novascular Disease
ary Renal Disease
Pacific People
Asian
NZ Maori
Caucasian / Other
Age in Years
munity House HD
Facility HD
PD
Home HD
.5 1 1.5 2 3
Hazard Ratioerebr
hera
oron
ype 
ype 
No
Dia
 / Re
 Prim
Comleast expensive setting in which to implement frequent/
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mortality risk with home HD is unclear. It is likely
that some of the benefit arises from patient character-
istics, rather than the treatment itself: undoubtedly
Table 2. Crude and Adjusted Effects of Mod
PD
Overall effect
Crude 2.78 (2.29-3.82)a
Adjusted (90-d lag) 2.18 (1.78-2.67)a
Interaction by follow-up period
2.5 y 2.74 (1.90-3.96)a
2.5 y 2.20 (1.72-2.82)a
Note: Values shown as hazard ratio for mortality (95% confiden
Abbreviations: HD, hemodialysis; PD, peritoneal dialysis; NA, n
aP 0.05 relative to reference modality.
Table 3. HD Treatment and Laboratory C
Home HD
Inception (n 714)
Missing
Data
HD session lengtha 0 (0)
3.5 h 22 (3)
3.5-3.9 h 14 (2)
4.0-4.4 h 164 (23)
4.5-4.9 h 75 (11)
5.0 h 439 (61)
HD session dosea
Kt/V 1.25 (1.11-1.42) 415 (73)
HD session frequencya 0 (0)
3/wk 4 (1)
3/wk 567 (79)
3-4.9/wk 109 (15)
5/wk 34 (5)
HD angioaccessa 0 (0)
Arteriovenous fistula 606 (85)
Arteriovenous graft 51 (7)
Central venous catheter 57 (8)
Hemodialyzer fluxa 0 (0)
High 179 (25)
Low 535 (75)
Hemoglobin (g/L)a 111 (100-122) 16 (2)
Erythropoietin use (yes)a 577 (82) 11 (2)
Serum ferritin (g/L)a 294 (154-473) 48 (7)
Serum phosphate (mmol/L)a 1.80 (1.49-2.20) 178 (25)
Serum calcium (mmol/L) 2.40 (2.27-2.53) 178 (25)
Note: Categorical variables are shown as number (percentage
are due to being unreported to the registry at dialysis inception o
status and serum calcium/phosphate values were collected from
restricted to those on 3-times-week regimens. Conversion factor
Abbreviations: ANZDATA, Australia and New Zealand Dialysis
aP 0.05.
604healthier patients are selected for this modality.7-9
However, the observed mortality benefit persists in
most studies, even after extensive statistical adjust-
ment for confounding by patient age and comorbid
on Mortality and Adjusted Interaction Effects
HD
Home Facility Community House
(reference) 2.50 (2.06-3.04)a 0.83 (0.36-1.89)
(reference) 2.17 (1.77-2.66)a 1.48 (0.64-3.40)
(reference) 3.65 (2.52-5.30)a NA
(reference) 1.56 (1.21-2.00)a 1.50 (0.58-3.51)
terval).
plicable.
teristics at Modality Inception by Modality
Facility HD Community House HD
Inception
(n  3,608)
Missing
Data Inception (n  59)
Missing
Data
5 (0) 1 (2)
113 (3) 1 (2)
25 (1) 2 (3)
,138 (59) 33 (56)
337 (9) 8 (14)
990 (27) 14 (24)
1.14 (1.00-1.30) 2,348 (70) 1.21 (1.06-1.41) 19 (32)
5 (0) 1 (2)
93 (3) 1 (2)
,376 (94) 54 (92)
109 (3) 2 (3)
25 (1) 1 (2)
141 (4) 2 (3)
,195 (33) 40 (68)
90 (3) 3 (5)
,182 (60) 14 (24)
4 (0) 1 (2)
,938 (81) 18 (31)
666 (18) 40 (68)
105 (94-118) 334 (9) 109 (100-121) 7 (12)
,509 (70) 175 (5) 42 (71) 6 (10)
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Community House HDconditions. Socioeconomic status and adherence, fac-
tors known to be independently associated with im-
proved survival, also are likely to contribute to the
observed mortality benefit seen with home HD.35-40
Home HD patients tend to be socioeconomically
advantaged, with stable and supportive social circum-
stances and greater adherence to dialysis, medication,
fluid restriction, and lifestyle measures.9,41-43 All these
factors engender flexibility and tolerance to dialysis in
the home setting, potentially leading to higher quality
HD treatments and a lower rate of technical adverse
events compared with facility HD.4,44,45 Of note, HD
treatment session length and schedule do not explain
the superior outcomes of patients on home HD therapy
in Australia or New Zealand.7 Rather, it is the general
experience of practitioners in this region that patients
undertaking home dialysis develop an enhanced cul-
ture of self-care that is the critical factor as an enabler
to improved outcomes.
As such, home HD is justifiable as a first choice for
patients who are clinically suitable. There are 3 types
of barriers to home HD: skill barriers, attitude barri-
ers, and social barriers. Skill barriers are probably the
most important limiting factor, although they some-
times can be overcome with training and simpler
“patient-friendly” machinery that is dedicated to home
HD.46-52 Attitude barriers are increasingly common
with the consumer- and service-oriented outlook of
many younger patients. Such patients often regard the
passive nature of facility dialysis as indicating “first-
class” treatment, and the do-it-yourself nature of home
HD, as being the “economy-class” option. However,
these and other attitude barriers often can be sur-
mounted by appropriate predialysis education and
advocacy by clinicians and patient groups.53-63
Perhaps the most modifiable barriers to home HD
are the social ones. In New Zealand, the perceived or
actual social disadvantages of home HD generally are
the same as reported elsewhere: disruptions to the
physical home environment, interference with family
life or overburdening of caregiver/helper support,
financial disadvantage from out-of-pocket expenses
such as utilities, fear of social isolation, and, in some
cultures, the unseemliness of bringing one’s illness
into the home environment.13-15,26,64-71 Community
house HD overcomes many of these social barriers. In
particular, the overburdening of families or caregivers
is one of the greatest concerns of dialysis patients,72,73
and those dialyzing in the community houses can do
so in an environment that is less intrusive for their
families, but still flexible enough to allow for employ-
ment and social obligations. Community house HD
also provides excellent support for patients who often
“buddy up” during HD training and also in the long
term when undertaking routine treatments in the com-
Am J Kidney Dis. 2013;61(4):598-607munity house. This is particularly popular with our
younger patients and has resulted in an optimistic and
sociable youth culture within the houses, leading in
turn to supportive networks and generally improved
health literacy. In our opinion, the community house
HD model of care is particularly suitable for patients
such as these, who are at risk with home therapies due
to risk-taking behavior and social pressures that often
override health responsibilities.
There are superadded costs with community house
HD for the provider compared to home HD. However,
these are minimal and offset to some degree by the
reduced requirement for dialysis machines: commu-
nity house HD patients share a machine as opposed to
those on home HD, who have their own. In New
Zealand, even at its most expensive, community house
HD is still markedly less costly for providers than
facility HD.74,75 Our experience indicates that the
following factors are key requirements for a success-
ful and sustainable community HD house. The initia-
tive should be developed in partnership with a chari-
table society, which almost guarantees a homey and
nonmedical rendering. In addition, the location of the
house should be driven by demand rather than oppor-
tunism. Since the completion of this study, Counties
Manukau District Health Board has entered into an-
other partnership with the Kidney Society Auckland
around an additional community HD house, with
continuing excellent uptake and results to date. Given
the good performance of the community house HD
model in both urban and rural New Zealand settings,
this approach is likely to be a viable option for large
urban centers in the United States and other countries.
As with all observational studies, associations do
not prove causality. There are a number of limitations
of this study. The small number of patients using
community house HD gives rise to wide confidence
intervals and the possibility of type 1 and type 2
errors. There also is potential for measurement error
from the recording of comorbid conditions, which is
based on the opinion of the treating nephrologist
rather than standardized definitions, and possible re-
sidual confounding from the limited collection of
comorbid conditions (eg, no collection of cognitive or
motor impairment) and absence of socioeconomic,
medication, and biochemical data in the analyses.
Finally, there is potential for bias in our study from
nonadherence to treatment prescriptions. Notwith-
standing these potential problems, registry-based stud-
ies such as ours are likely to remain a useful guide to
clinical practice, especially if they involve contempo-
rary cohorts arising from modern selection criteria
and robust methods for statistical adjustment.
In conclusion, our study demonstrates that commu-
nity house HD can improve the uptake of home HD in
605
Marshall et alurban settings by addressing many of the social barri-
ers that impede the uptake of home dialysis, espe-
cially in younger patients.
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